Canadian Blood Services

Canadian Bllood Services

Canadian Blood Cervices

Duncheng Wang

Mark D Scott

Wendy M Toyofuku

This invention relates to acellular-based therapies for decreasing the level of regulatory T cells (Treg) and/or increasing the level of pro-inflammatory T cells (Th17) to favor immune stimulation. To provide these therapeutic effects, an allogeneic leukocyte population is contacted with another leukocyte population and the acellular components produced are isolated. The leukocyte populations are contacted so as to allow pro-inflammatory allo-recognition. Acellular-based preparations and processes for achieving therapy are also provided.

Acellular pro-inflammatory compositions, process for making same and methods of using same

This disclosure relates to a cellular-based therapies for modulating the level of regulatory T cells (Treg) and/or the level of pro-inflammatory T cells (Th17/Th1). To provide these therapeutic effects, a combination comprising at least one a cellular pro-tolerogenic preparation and at least one a cellular pro-inflammatory preparation are administered sequentially.

Combination therapy of acellular pro-tolerogenic and pro-inflammatory preparations for modulating the immune system

This invention relates to cellular-based therapies for increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. To provide these therapeutic effects, a non-proliferative allogeneic leukocyte population is contacted with another leukocyte population. The non-proliferative allogeneic leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition with the latter leukocyte population. Cellular-based preparations and processes for achieving cellular therapy are also provided.

Method for inducing immune tolerance using non-proliferative polymer-modified allogeneic leukocytes

This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Acellular pro-tolerogenic compositions, process for making such composition as well as therapeutic uses of such compositions are also provided.

Acellular pro-tolerogenic compositions and process for making same

This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Therapeutic uses intended for the treatment/prevention of auto-immune diseases of such compositions are also provided.

Acellular pro-tolerogenic compositions for the treatment/prevention of auto-immune diseases

This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Therapeutic uses for preventing or limiting graft rejection and GVHD of such compositions are also provided.

Acellular pro-tolerogenic compositions for treatment/prevention of graft rejection

This invention relates to cellular-based therapies for increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. To provide these therapeutic effects, two allogeneic leukocyte populations are contacted (in vivo, in vitro or ex vivo) and one of these leukocyte population is modified to bear on its surface a low-immunogenic biocompatible polymer so as to prevent pro-inflammatory allo-recognition. Cellular-based preparations and processes for achieving cellular therapy are also provided.

Growing community of inventors

Greenville, NC, United States of America

Duncheng Wang